This is a preview of subscription content, log in via an institution to check access.
References
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722–4729.
Cloughesy T, Prados M, Wen P, et al.: A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with irinotecan prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Paper presented at Society for Neuro-Oncology Annual meeting. Dallas, TX; November 15–18, 2007.
Dings RP, Loren M, Heun H, et al.: Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007, 13:3395–3402.
Mohile NA, Abrey LE, Lymberis SC, et al.: A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007, 25(Suppl):2028.
Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83–95.
Chen W, Delaloye S, Silverman DH, et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25:4714–4721.
Rights and permissions
About this article
Cite this article
Abrey, L.E. Bevacizumab in recurrent malignant glioma. Curr Neurol Neurosci Rep 8, 233–234 (2008). https://doi.org/10.1007/s11910-008-0035-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-008-0035-9